May 2010

Where Do We Stand With REMS?

August 15, 2011

Cover Story

With the FDA extending the public comment period on the development of a Risk Evaluation and Mitigation Strategy (REMS) for opioid drug products until October 2010, there's still time for physicians, pharmacists, and patients to make their voices heard.

x